Wild type (WT) CD1, C57BL/6J, and CX3CR1+/GFP
2 mice were used. All studies adhered to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the Animal Care and Use Committee of the National Eye Institute. For whole mount pigment bleaching and immunostaining, mouse eyes were enucleated, fixed in 4% paraformaldehyde PBS for 30 minutes to 4 hours, and the anterior segments were removed before or after melanin bleaching. For whole mount staining, primary and secondary antibodies were treated at 4°C for 3 and 2 days, respectively. For 10 μm cryosectioned retina tissues, primary and secondary antibodies were treated at room temperature for 1.5 hours and 30 minutes, respectively. The primary antibodies used were rabbit anti-cone arrestin (CAR; Millipore, Billerica, MA), calbindin (Calbiochem, La Jolla, CA), protein kinase C alpha (PKCα; Sigma-Aldrich, St. Louis, MO), and ionized calcium-binding adapter molecule 1 (Iba-1; Wako, Richmond, VA), chicken anti-S-opsin, and green fluorescent protein (GFP; Millipore), rat anti-CD11b (Serotec, Oxford, England, UK), mouse anti-glutamine synthase (GS; Millipore), and ezrin (Thermo Scientific, Rockford, IL). The relevant secondary antibodies conjugated with Alexa Fluor 488 or 555 (Life Technologies, Carlsbad, CA) were used at a dilution of 1:1000. Bovine serum albumin (1%) and 0.2% or 0.5% Triton X-100 in PBS was used for blocking and antibody treatment. All experiments were repeated separately, at least twice, using multiple retinas.